Applied DNA Sciences Inc. Reports 2026 Q1 Results: A Focused Pivot Toward Digital Assets

For the quarter ending December 31, 2025, Applied DNA Sciences reported a net loss of $18.60 million, a notable increase from the $2.66 million loss reported in the same period a year prior. Revenue saw a modest uptick to $565,300, compared to $1.19 million in Q1 2025, indicating a complex interplay of growth in certain product lines while facing stark declines in service revenues.

The company's product revenues increased by 12% year-over-year, driven primarily by a large-scale DNA manufacturing customer. However, service revenues plummeted by an astonishing 97%, from $374,444 in Q1 2025 to just $10,301. This decline is attributed to the cessation of textile isotopic testing services, which formed a core part of the company's service offerings.

Operating expenses surged significantly, with selling, general, and administrative expenses skyrocketing by 420% to $13.34 million. This dramatic rise was primarily due to increased consulting fees associated with the digital asset strategy and substantial payroll expenses, including severance payments for the former CEO. Research and development expenses saw a decrease to $458,562, reflecting a focus on cost management amid the restructuring efforts.

In October 2025, Applied DNA Sciences launched its DAT strategy, securing $26.8 million in gross proceeds from a Private Placement. This strategy emphasizes the accumulation and management of BNB, the native cryptocurrency of the Binance ecosystem, through staking and yield generation opportunities. The company is currently in the process of establishing a robust framework to effectively implement this strategy.

The Board of Directors authorized a restructuring plan in October 2025, which resulted in a significant reduction of the workforce—approximately 60% of employees were laid off. This move, which incurred pre-tax charges of around $1.2 million, is aimed at streamlining operations and reallocating resources to enhance the BNB Strategy.

As of December 31, 2025, Applied DNA Sciences reported total assets of $20.69 million, up from $15.97 million in the previous year. The company held $2.45 million in cash and cash equivalents, alongside a working capital of $2.91 million. However, the net loss for the quarter contributed to an accumulated deficit of $397.79 million, highlighting the ongoing financial challenges.

The cash flow statement indicates a net change in cash of $776,700 for the quarter, primarily driven by financing activities. The company utilized $5.55 million in operating cash, demonstrating the pressures on liquidity as it invests heavily in its digital asset initiatives.

Applied DNA Sciences Inc. is at a crossroads, navigating a significant transition as it focuses on its BNB Strategy while managing the fallout from operational restructuring. The financial results reflect a blend of growth opportunities in digital assets and the challenges inherent in the biotechnology sector.

The company's strategic pivot towards digital asset management signals a forward-thinking approach in a rapidly evolving market landscape. However, the steep increase in operational losses and declining service revenues underlines the critical need for effective execution of its strategic initiatives. As the company positions itself in the cryptocurrency space, investors will be keenly watching its ability to convert these plans into sustainable financial performance in the months ahead.